ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease

Evidence from a peripheral model

Barbara Borroni, Francesca Colciaghi, Lucia Pastorino, Silvana Archetti, Paola Corsini, Flaminio Cattabeni, Monica Di Luca, Alessandro Padovani

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Three major amyloid precursor protein (APP) forms with apparent molecular weight ranging from 106 to 130 kDa are present in human platelets. Alzheimer disease (AD) is associated with a decreased APP forms ratio (APPr) between the three major forms. A total of 25 mild to moderate AD patients were investigated. Platelet APPr was studied before and after 30 days of acetylcholinesterase-inhibitor treatment (donepezil, 5 mg daily). Patients were grouped into non-ε4 carriers and ε4 carriers according to apolipoprotein E (ApoE) genotype. At baseline, all patients showed low APPr levels and no significant difference was found between the two ApoE subgroups. After treatment, although a marked improvement in APPr was observed in most patients, non-ε4 carriers displayed a higher increase compared to ε4 carriers (P

Original languageEnglish
Pages (from-to)195-200
Number of pages6
JournalEuropean Neuropsychopharmacology
Volume12
Issue number3
DOIs
Publication statusPublished - 2002

Fingerprint

Amyloid beta-Protein Precursor
Apolipoproteins E
Alzheimer Disease
Genotype
Blood Platelets
Cholinesterase Inhibitors
Molecular Weight
donepezil
Therapeutics

Keywords

  • Alzheimer disease
  • Amyloid precursor protein (APP)
  • Apolipoprotein E
  • Donepezil

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease : Evidence from a peripheral model. / Borroni, Barbara; Colciaghi, Francesca; Pastorino, Lucia; Archetti, Silvana; Corsini, Paola; Cattabeni, Flaminio; Di Luca, Monica; Padovani, Alessandro.

In: European Neuropsychopharmacology, Vol. 12, No. 3, 2002, p. 195-200.

Research output: Contribution to journalArticle

Borroni, B, Colciaghi, F, Pastorino, L, Archetti, S, Corsini, P, Cattabeni, F, Di Luca, M & Padovani, A 2002, 'ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: Evidence from a peripheral model', European Neuropsychopharmacology, vol. 12, no. 3, pp. 195-200. https://doi.org/10.1016/S0924-977X(02)00013-5
Borroni, Barbara ; Colciaghi, Francesca ; Pastorino, Lucia ; Archetti, Silvana ; Corsini, Paola ; Cattabeni, Flaminio ; Di Luca, Monica ; Padovani, Alessandro. / ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease : Evidence from a peripheral model. In: European Neuropsychopharmacology. 2002 ; Vol. 12, No. 3. pp. 195-200.
@article{97c2ba345c8c484f98c72c0607ee7ee0,
title = "ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: Evidence from a peripheral model",
abstract = "Three major amyloid precursor protein (APP) forms with apparent molecular weight ranging from 106 to 130 kDa are present in human platelets. Alzheimer disease (AD) is associated with a decreased APP forms ratio (APPr) between the three major forms. A total of 25 mild to moderate AD patients were investigated. Platelet APPr was studied before and after 30 days of acetylcholinesterase-inhibitor treatment (donepezil, 5 mg daily). Patients were grouped into non-ε4 carriers and ε4 carriers according to apolipoprotein E (ApoE) genotype. At baseline, all patients showed low APPr levels and no significant difference was found between the two ApoE subgroups. After treatment, although a marked improvement in APPr was observed in most patients, non-ε4 carriers displayed a higher increase compared to ε4 carriers (P",
keywords = "Alzheimer disease, Amyloid precursor protein (APP), Apolipoprotein E, Donepezil",
author = "Barbara Borroni and Francesca Colciaghi and Lucia Pastorino and Silvana Archetti and Paola Corsini and Flaminio Cattabeni and {Di Luca}, Monica and Alessandro Padovani",
year = "2002",
doi = "10.1016/S0924-977X(02)00013-5",
language = "English",
volume = "12",
pages = "195--200",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier Science B.V.",
number = "3",

}

TY - JOUR

T1 - ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease

T2 - Evidence from a peripheral model

AU - Borroni, Barbara

AU - Colciaghi, Francesca

AU - Pastorino, Lucia

AU - Archetti, Silvana

AU - Corsini, Paola

AU - Cattabeni, Flaminio

AU - Di Luca, Monica

AU - Padovani, Alessandro

PY - 2002

Y1 - 2002

N2 - Three major amyloid precursor protein (APP) forms with apparent molecular weight ranging from 106 to 130 kDa are present in human platelets. Alzheimer disease (AD) is associated with a decreased APP forms ratio (APPr) between the three major forms. A total of 25 mild to moderate AD patients were investigated. Platelet APPr was studied before and after 30 days of acetylcholinesterase-inhibitor treatment (donepezil, 5 mg daily). Patients were grouped into non-ε4 carriers and ε4 carriers according to apolipoprotein E (ApoE) genotype. At baseline, all patients showed low APPr levels and no significant difference was found between the two ApoE subgroups. After treatment, although a marked improvement in APPr was observed in most patients, non-ε4 carriers displayed a higher increase compared to ε4 carriers (P

AB - Three major amyloid precursor protein (APP) forms with apparent molecular weight ranging from 106 to 130 kDa are present in human platelets. Alzheimer disease (AD) is associated with a decreased APP forms ratio (APPr) between the three major forms. A total of 25 mild to moderate AD patients were investigated. Platelet APPr was studied before and after 30 days of acetylcholinesterase-inhibitor treatment (donepezil, 5 mg daily). Patients were grouped into non-ε4 carriers and ε4 carriers according to apolipoprotein E (ApoE) genotype. At baseline, all patients showed low APPr levels and no significant difference was found between the two ApoE subgroups. After treatment, although a marked improvement in APPr was observed in most patients, non-ε4 carriers displayed a higher increase compared to ε4 carriers (P

KW - Alzheimer disease

KW - Amyloid precursor protein (APP)

KW - Apolipoprotein E

KW - Donepezil

UR - http://www.scopus.com/inward/record.url?scp=0036253645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036253645&partnerID=8YFLogxK

U2 - 10.1016/S0924-977X(02)00013-5

DO - 10.1016/S0924-977X(02)00013-5

M3 - Article

VL - 12

SP - 195

EP - 200

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 3

ER -